In VitroActivities and Spectrum of the Novel Fluoroquinolone Lascufloxacin (KRP-AM1977).
Lascufloxacin exhibited a broad spectrum of activity against various clinical isolates. Furthermore, lascufloxacin showed the most potent activity against Gram-positive bacteria among the quinolones tested and incomplete cross-resistance against existing quinolone-resistant strains. Enzymatic analysis indicated that lascufloxacin had potent inhibitory activity against both wild-type and mutated target enzymes. These results suggest that lascufloxacin may be useful in treating infections caused by various pathogens, including quinolone-resistant strains.
Watarase Research Center, Kyorin Pharmaceutical Co., Ltd., Tochigi, Japan ryuuta.kishii@mb.kyorin-pharm.co.jp.
Ryuta
R
Kishii
Watarase Research Center, Kyorin Pharmaceutical Co., Ltd., Tochigi, Japan.
Yuko
Y
Yamaguchi
Watarase Research Center, Kyorin Pharmaceutical Co., Ltd., Tochigi, Japan.
Masaya
M
Takei
D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D024881:Drug Resistance, Bacterial; D004926:Escherichia coli / Q000187:drug effects* / Q000302:isolation & purification; D024841:Fluoroquinolones / Q000494:pharmacology*; D006801:Humans; D008826:Microbial Sensitivity Tests; D013211:Staphylococcus aureus / Q000187:drug effects* / Q000302:isolation & purification; D013296:Streptococcus pneumoniae / Q000187:drug effects* / Q000302:isolation & purification
D000900:Anti-Bacterial Agents; D024841:Fluoroquinolones; C000626327:lascufloxacin
antimicrobial activity; antimicrobial agents; quinolones